ENTX Entera Bio Total Debt to Capital

Corporate emblem and logo of Entera Bio Ltd (ENTX)

Entera Bio Ltd. (ENTX) develops tablet alternatives to injections, ensuring global reach with low production costs. The business moat is based on ProNeura platform patents and user-friendly software that shuts out competitors. Logistics optimization through the elimination of cold chain requirements enhances margins. The company's price evolution with the 0.06 indicator is illustrated below.

ENTX: Entera Bio Corp Total Debt to Capital 07/04/2022 - 10/28/2026

Analytical breakdowns and data insights for company Entera Bio (ENTX)

- price and consensus price forecast:
Price Chart Entera Bio Ltd|ENTX - Forecast Levels Chart
- market capitalization data:
Market Capitalization Entera Bio|ENTX - Value Adjusted for Debt and Cash
- book capitalization data:
Book Value per Share Entera Bio|ENTX - Book Capitalization|Market Value to Book Value Ratio enterabio.com|ENTX - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Entera Bio Ltd.|ENTX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Entera Bio Ltd|ENTX - Company Aggregate Debts|Debt to Book Value Entera Bio|ENTX - Company Long-Term Loans and Borrowings|Company Short-Term Debt Entera Bio
Comprehensive company analysis:ENTX - Entera Bio Ltd.
Brand item of Entera Bio

Entera Bio Ltd. (ENTX) specializes in the innovative development of oral formulations for injectable drugs, which entails high R&D risks. By analyzing the debt-to-equity chart, an investor assesses the balance between borrowed funds and equity, where excessive leverage increases debt service costs, while a lack thereof may limit the profitability and scaling pace of the pharmaceutical business.

Key competitors

Debt to Equity Haleon HLN|Aggregate Debt to Equity Kenvue Inc|Verona Pharma Corp (VRNA) - Total Debt to Capital|All Debt to Shareholders' Equity Ratio Jyong Bio (MENS)|Total Debt to Capital LGND (Ligand Pharmaceuticals)|amneal.com - Total Debt to Capital|Debt to Equity Perrigo (PRGO)|ALVO: All Debt to Shareholders' Equity Ratio|LQDA (Liquidia Technologies) - Debt to Equity|Galapagos Corp (GLPG) - Total Debt to Equity Ratio|ANIP (ANI Pharmaceuticals) - Total Debt to Capital|Total Debt to Capital mannkindcorp.com (MNKD)|Amphastar Pharmaceuticals, Inc. (AMPH) - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio PCRX (Pacira Pharmaceuticals)|SPRY: Debt to Equity|TBPH - Debt to Capital|Total Debt to Equity Ratio Aquestive Therapeutics AQST|SCPH - Aggregate Debt to Capital|Total Debt to Capital tectonictx.com TECX|Tonix Pharma (TNXP) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital SXTC (SXT Pharmaceuticals)|Debt to Capital EPRX|BioHarvest Sciences (BHST) - Debt to Equity|All Debt to Shareholders' Equity Ratio invizyne.com (EXOZ)|ORMP: Total Debt to Capital|MindWalk Holdings, Inc. - Debt to Capital|ABVC BioPharma Inc (ABVC) - Debt to Equity|Cumberland Corp (CPIX) - Debt to Equity Ratio|QNTM - Total Debt to Equity Ratio|fibrogen.com (FGEN) - Aggregate Debt to Capital|Total Debt to Capital TELO (Telomir Pharmaceuticals, Inc.)|Debt to Capital RANI|Synergy CHC Corp (SNYR) - Debt to Equity|All Debt to Shareholders' Equity Ratio rallybio.com (RLYB)|Total Debt to Capital LEXX (Lexaria Bioscience Corp.)|PULM - Total Debt to Capital|Total Debt to Equity Ratio Pheton (PTHL)|APM - All Debt to Shareholders' Equity Ratio|Lyra Therapeutics, Inc (LYRA) - Total Debt to Capital|Impact BioMedical, Inc. (IBO) - Debt to Equity|TNFA: Total Debt to Capital|Total Debt to Capital Coefficient YCBD|PainReform - Debt to Equity|Debt to Capital altamiratherapeutics.com CYTO|Total Debt to Equity Ratio Lipella|OptiNose Corp - All Debt to Shareholders' Equity Ratio|PIRS - Debt to Equity|procapsgroup.com (PROC) - Debt to Equity|PTPI - Total Debt to Equity Ratio|Qilian International Holding Group (QLI) - Aggregate Debt to Capital|Total Debt to Capital ACELYRIN, Inc. (SLRN)|Debt to Equity Ratio TFF Pharmaceuticals, Inc (TFFP)